AMARIN CORP PLC

Amarin Corporation PLC’s surge on the Frankfurt Stock Exchange underscores its growing promise in cardiovascular therapeutics, driven by a robust pipeline, key partnerships, and strong investor confidence.

Amarin Corporation PLC’s upcoming Q4/2025 results reveal a recovering but volatile stock, spotlighting its cardiovascular drug pipeline and investor hopes.

Amarin’s stock lingers at €7.08 amid a pending US Supreme Court “skinny‑label” patent hearing that could reshape its future.

Amarin faces a Supreme Court patent battle over its “skinny label” strategy—will the ruling protect Vascepa’s exclusivity and reshape biotech patent law?

Amarin’s upcoming Supreme Court case on its “skinny‑label” patent could reshape the biotech market and its 12.90 EUR stock price, offering investors new insights.

Amarin’s latest REDUCE‑IT data confirms icosapent ethyl’s heart‑protective benefits, bolstering its financial outlook and attracting investors amid market volatility.

Amarin’s Q3 2025 results and AHA presentation confirm its cardiovascular therapy’s strength, while stock stays mid‑range, hinting at recovery potential.

Amarin Corporation PLC’s fluctuating stock and market challenges highlight the tough biotech landscape for cardiovascular therapies—can the firm turn innovation into sustained growth?

Amarin Corporation PLC is a biotech leader focused on cardiovascular therapeutics, driving innovative treatments and strong market growth in a volatile industry.

Amarin Corporation PLC, a biotechnology company listed on the Frankfurt Stock Exchange, has demonstrated resilience and growth potential in the health care industry, particularly in cardiovascular therapeutics, with a strong market position and prom…